Drug interactions
Erdafitinib + Metformin-pioglitazone
Severity: Moderate
Erdafitinib and Metformin-pioglitazone: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Erdafitinib may inhibit OCT2, a transporter involved in renal secretion of metformin. Metformin levels could rise, increasing gastrointestinal effects and potentially the risk of lactic acidosis.
What this interaction means in plain words
Erdafitinib and Metformin-pioglitazone can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Erdafitinib belongs to Oncology; Metformin-pioglitazone belongs to Endocrine.
Why it happens
Inhibition of renal OCT2-mediated metformin secretion.
What to do
Monitor renal function and metformin tolerability. Consider reducing the metformin dose if adverse effects occur.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Erdafitinib and Metformin-pioglitazone, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Metformin-pioglitazone
Other interactions of Erdafitinib
Frequently asked questions
Can I take Erdafitinib with Metformin-pioglitazone?
MediHelp rates the interaction as moderate. Erdafitinib and Metformin-pioglitazone can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Erdafitinib may inhibit OCT2, a transporter involved in renal secretion of metformin. Metformin levels could rise, increasing gastrointestinal effects and potentially the risk of lactic acidosis.
How serious is the interaction between Erdafitinib and Metformin-pioglitazone?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor renal function and metformin tolerability. Consider reducing the metformin dose if adverse effects occur.
What other medicines interact with Metformin-pioglitazone?
MediHelp also lists interactions of Metformin-pioglitazone with, for example, Contrast media, Diatrizoate meglumine / diatrizoate, Diatrizoate. The full list is on the Metformin-pioglitazone page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
